125 related articles for article (PubMed ID: 22563468)
1. Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trial.
Miki K; Maekura R; Nagaya N; Nakazato M; Kimura H; Murakami S; Ohnishi S; Hiraga T; Miki M; Kitada S; Yoshimura K; Tateishi Y; Arimura Y; Matsumoto N; Yoshikawa M; Yamahara K; Kangawa K
PLoS One; 2012; 7(5):e35708. PubMed ID: 22563468
[TBL] [Abstract][Full Text] [Related]
2. Effect of Regular, Low-Dose, Extended-release Morphine on Chronic Breathlessness in Chronic Obstructive Pulmonary Disease: The BEAMS Randomized Clinical Trial.
Ekström M; Ferreira D; Chang S; Louw S; Johnson MJ; Eckert DJ; Fazekas B; Clark KJ; Agar MR; Currow DC;
JAMA; 2022 Nov; 328(20):2022-2032. PubMed ID: 36413230
[TBL] [Abstract][Full Text] [Related]
3. Effects of ghrelin treatment on exertional dyspnea in COPD: an exploratory analysis.
Miki K; Maekura R; Nagaya N; Miki M; Kitada S; Yoshimura K; Mori M; Kangawa K
J Physiol Sci; 2015 May; 65(3):277-84. PubMed ID: 25724656
[TBL] [Abstract][Full Text] [Related]
4. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
Katakami N; Uchino J; Yokoyama T; Naito T; Kondo M; Yamada K; Kitajima H; Yoshimori K; Sato K; Saito H; Aoe K; Tsuji T; Takiguchi Y; Takayama K; Komura N; Takiguchi T; Eguchi K
Cancer; 2018 Feb; 124(3):606-616. PubMed ID: 29205286
[TBL] [Abstract][Full Text] [Related]
5. Melatonin supplementation enhances pulmonary rehabilitation outcomes in COPD: a randomized, double-blind, placebo-controlled study.
Viana SMDNR; de Bruin VMS; Vasconcelos RS; Nogueira ANC; Mesquita R; de Bruin PFC
Respir Med; 2023 Dec; 220():107441. PubMed ID: 37944829
[TBL] [Abstract][Full Text] [Related]
6. Heme metabolism genes Downregulated in COPD Cachexia.
Wilson AC; Kumar PL; Lee S; Parker MM; Arora I; Morrow JD; Wouters EFM; Casaburi R; Rennard SI; Lomas DA; Agusti A; Tal-Singer R; Dransfield MT; Wells JM; Bhatt SP; Washko G; Thannickal VJ; Tiwari HK; Hersh CP; Castaldi PJ; Silverman EK; McDonald MN
Respir Res; 2020 May; 21(1):100. PubMed ID: 32354332
[TBL] [Abstract][Full Text] [Related]
7. Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia.
Herodes M; Anderson LJ; Shober S; Schur EA; Graf SA; Ammer N; Salas R; Marcelli M; Garcia JM
J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):835-846. PubMed ID: 36860137
[TBL] [Abstract][Full Text] [Related]
8. A phase II, open-label clinical trial on the combination therapy with medium-chain triglycerides and ghrelin in patients with chronic obstructive pulmonary disease.
Miki K; Kitada S; Miki M; Hui SP; Shrestha R; Yoshimura K; Tsujino K; Kagawa H; Oshitani Y; Kida H; Maekura R; Kangawa K
J Physiol Sci; 2019 Nov; 69(6):969-979. PubMed ID: 31595463
[TBL] [Abstract][Full Text] [Related]
9. Acyl ghrelin increases cardiac output while preserving right ventricular-pulmonary arterial coupling in heart failure.
Erhardsson M; Faxén UL; Venkateshvaran A; Hage C; Pironti G; Thorvaldsen T; Webb DL; Hellström PM; Andersson DC; Ståhlberg M; Lund LH
ESC Heart Fail; 2024 Feb; 11(1):601-605. PubMed ID: 38030138
[TBL] [Abstract][Full Text] [Related]
10. Tadalafil for veterans with chronic obstructive pulmonary disease-pulmonary hypertension: A multicenter, placebo-controlled randomized trial.
Maron BA; Choudhary G; Goldstein RL; Garshick E; Jankowich M; Tucker TJS; LaCerda KA; Hattler B; Dempsey EC; Sadikot RT; Shapiro S; Rounds SI; Goldstein RH
Pulm Circ; 2022 Jan; 12(1):e12043. PubMed ID: 35506072
[TBL] [Abstract][Full Text] [Related]
11. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial).
Stewart Coats AJ; Ho GF; Prabhash K; von Haehling S; Tilson J; Brown R; Beadle J; Anker SD;
J Cachexia Sarcopenia Muscle; 2016 Jun; 7(3):355-65. PubMed ID: 27386169
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled superiority trial of the Yiqigubiao pill for the treatment of patients with chronic obstructive pulmonary disease at a stable stage.
Li FS; Zhang YL; Li Z; Xu D; Liao CY; Ma H; Gong L; Su J; Sun Q; Xu Q; Gao Z; Wang L; Jing J; Wang J; Jiang M; Tian G; Hasan B
Exp Ther Med; 2016 Oct; 12(4):2477-2488. PubMed ID: 27698749
[TBL] [Abstract][Full Text] [Related]
13. Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia.
Axiak-Bechtel SM; Leach SB; Newton-Northup JR; Milner RJ; Fox-Alvarez SA; Fagman LI; Young KA; Tate DJ; Wright ZM; Chretin JD; Allen JW; Yoshimoto SK; Selting KA; Flesner BK; White CR; Mills T; Aherne M; Bergman PJ; Qi L; Gruber KA; Callahan MF
J Vet Intern Med; 2023; 37(6):2344-2355. PubMed ID: 37897303
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014.
von Haehling S; Anker SD
J Cachexia Sarcopenia Muscle; 2014 Dec; 5(4):261-3. PubMed ID: 25384990
[TBL] [Abstract][Full Text] [Related]
15. Ghrelin administration for chronic respiratory failure: a randomized dose-comparison trial.
Matsumoto N; Miki K; Tsubouchi H; Sakamoto A; Arimura Y; Yanagi S; Iiboshi H; Yoshida M; Souma R; Ishimoto H; Yamamoto Y; Yatera K; Yoshikawa M; Sagara H; Iwanaga T; Mukae H; Maekura R; Kimura H; Nakazato M; Kangawa K
Lung; 2015 Apr; 193(2):239-47. PubMed ID: 25634352
[TBL] [Abstract][Full Text] [Related]
16. Ghrelin improves body weight loss and skeletal muscle catabolism associated with angiotensin II-induced cachexia in mice.
Sugiyama M; Yamaki A; Furuya M; Inomata N; Minamitake Y; Ohsuye K; Kangawa K
Regul Pept; 2012 Oct; 178(1-3):21-8. PubMed ID: 22750276
[TBL] [Abstract][Full Text] [Related]
17. Identification of three exercise-induced mortality risk factors in patients with COPD.
Yoshimura K; Maekura R; Hiraga T; Miki K; Kitada S; Miki M; Tateishi Y; Mori M
COPD; 2014 Dec; 11(6):615-26. PubMed ID: 24914923
[TBL] [Abstract][Full Text] [Related]
18. Combined Exercise Training and Nutritional Interventions or Pharmacological Treatments to Improve Exercise Capacity and Body Composition in Chronic Obstructive Pulmonary Disease: A Narrative Review.
Brauwers B; Machado FVC; Beijers RJHCG; Spruit MA; Franssen FME
Nutrients; 2023 Dec; 15(24):. PubMed ID: 38140395
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and outcomes of cachexia in Asia: Working Consensus Report from the Asian Working Group for Cachexia.
Arai H; Maeda K; Wakabayashi H; Naito T; Konishi M; Assantachai P; Auyeung WT; Chalermsri C; Chen W; Chew J; Chou MY; Hsu CC; Hum A; Hwang IG; Kaido T; Kang L; Kamaruzzaman SB; Kim M; Lee JSW; Lee WJ; Liang CK; Lim WS; Lim JY; Lim YP; Lo RS; Ong T; Pan WH; Peng LN; Pramyothin P; Razalli NH; Saitoh M; Shahar S; Shi HP; Tung HH; Uezono Y; von Haehling S; Won CW; Woo J; Chen LK
J Cachexia Sarcopenia Muscle; 2023 Oct; 14(5):1949-1958. PubMed ID: 37667992
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of interventions to alter measures of fat-free mass in people with COPD: a systematic review and meta-analysis.
Jenkins AR; Gaynor-Sodeifi K; Lewthwaite H; Triandafilou J; Belo LF; de Oliveira MF; Jensen D
ERJ Open Res; 2023 Jul; 9(4):. PubMed ID: 37529637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
